A phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma.

I. ABSTRACT

Patients in (10) were enrolled at 1 US site between May 2016 and January 2017.

B. Patient Characteristics

C. Response by RECIST 1.1

D. Percentage change of Tumor Size (sum) over time from baseline

E. Maximal percentage change of tumor size (sum) by patient

F. Percentage change of CA19.9 over time (abnormal CA19.9 at baseline)

H. Time on Therapy, Reason for Stopping, Response, Survival

I. Imaging

J. Toxicities

**Adverse Events Grade 3-5**

**Serious Adverse Events All Grades**

**References:**


**ACKNOWLEDGEMENTS**

With sincere appreciation to the Seena Magowitz Foundation, Mattress Firm, Bristol Myers Squibb, Tgen Foundation, HonorHealth Foundation, and Stand Up To Cancer. Special thanks to our patients and families for their participation.

**V. CONCLUSIONS AND NEXT STEPS**

- Although a small study, the high response rate is encouraging.
- The study is being expanded to 25 patients.
- Future exploratory analyses will include inflammatory biomarkers, microbiome studies to correlate with response.
- Quality of life (QOL) analysis is underway.

**Author contact:** Erikut.Borazanci@honorhealth.com